Futibatinib
Orphan DrugFDA Approved
Contents
Description
Futibatinib is an oral irreversible FGFR1-4 inhibitor approved for previously treated unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements. It is a precision-oncology orphan therapy with a narrow biomarker-defined population. This makes it a strong fit for rare-disease and specialty-access datasets.
Indications & Therapeutic Use
intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Buy / Source Futibatinib — GNH India
6 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Futibatinib products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Futibatinib
| Generic Name | futibatinib |
| Brands | 1 brand available |
| Active Ingredient | futibatinib |
| Drug Class | intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement |
| Manufacturer | Taiho Oncology |
| Dosage Forms | Oral tablet |
| Medical Code | L01EN |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02052778 |
| Countries | 2 countries |
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes